MetaCap

eXoZymes (EXOZ) vs Metagenomi Therapeutics (MGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Metagenomi Therapeutics (MGX) has outperformed eXoZymes (EXOZ) over the past year, losing 62.6% versus a loss of 81.8%. eXoZymes is the larger company by market cap ($27.4 million vs $21.4 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EXOZ-81.84%MGX-62.58%
+26%-31%-87%
Nov 21, 20251 yearNov 20, 2026
EXOZ-73.88%MGX-68.96%
+132%+24%-84%
Nov 11, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EXOZ versus MGX key metrics
MetricEXOZMGX
Share price$2.91$0.565
Market cap$27.42M$21.36M
1-day change-14.05%-7.95%
YTD return-73.35%-65.12%
1-year return-81.84%-62.58%
EPS (TTM)$-1.16$-2.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$25.21M
Revenue growth (YoY)—-51.79%
Net income (latest FY)$-9.16M$-87.87M
Operating margin—-380.85%
Net margin—-348.54%
52-week high$16.16$1.87
52-week low$2.81$0.562
Distance from 52-week high-82.02%-69.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside—+1138.94%
Average volume10.14K163.21K
Shares outstanding9.44M37.81M
Employees32113
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MGX has outperformed EXOZ by 19.3 percentage points over the past year.

About eXoZymes

EXOZ stock →

eXoZymes, Inc. operates as a development stage biotechnology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 32 employees

About Metagenomi Therapeutics

MGX stock →

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

EXOZ vs MGX FAQ

Which is bigger, eXoZymes or Metagenomi Therapeutics?

eXoZymes (EXOZ) is larger, with a market capitalization of $27.42M compared with $21.36M for Metagenomi Therapeutics (MGX).

Which stock has performed better over the past year, EXOZ or MGX?

MGX returned -62.58% over the past 12 months, compared with -81.84% for EXOZ (price return, excluding dividends). Past performance does not predict future results.

Are eXoZymes and Metagenomi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons